EA201892051A1 - Фармацевтические композиции для лечения злокачественного новообразования - Google Patents
Фармацевтические композиции для лечения злокачественного новообразованияInfo
- Publication number
- EA201892051A1 EA201892051A1 EA201892051A EA201892051A EA201892051A1 EA 201892051 A1 EA201892051 A1 EA 201892051A1 EA 201892051 A EA201892051 A EA 201892051A EA 201892051 A EA201892051 A EA 201892051A EA 201892051 A1 EA201892051 A1 EA 201892051A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- formation
- pharmaceutical compositions
- malignant non
- malignant
- Prior art date
Links
- 230000003211 malignant effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 abstract 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 abstract 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308341P | 2016-03-15 | 2016-03-15 | |
| PCT/US2017/022386 WO2017160895A1 (en) | 2016-03-15 | 2017-03-15 | Pharmaceutical compositions for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892051A1 true EA201892051A1 (ru) | 2019-02-28 |
Family
ID=58428389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892051A EA201892051A1 (ru) | 2016-03-15 | 2017-03-15 | Фармацевтические композиции для лечения злокачественного новообразования |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190091252A1 (enExample) |
| EP (1) | EP3429583A1 (enExample) |
| JP (1) | JP2019508443A (enExample) |
| KR (1) | KR20180116437A (enExample) |
| CN (1) | CN109195601A (enExample) |
| AU (1) | AU2017232348A1 (enExample) |
| BR (1) | BR112018068027A2 (enExample) |
| CA (1) | CA3016446A1 (enExample) |
| EA (1) | EA201892051A1 (enExample) |
| IL (1) | IL261278A (enExample) |
| MX (1) | MX2018011101A (enExample) |
| PH (1) | PH12018501943A1 (enExample) |
| WO (1) | WO2017160895A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220098082A (ko) * | 2018-07-09 | 2022-07-11 | 타임, 인크. | 종양 감소 제형 및 그의 사용 방법 |
| AU2020276605A1 (en) | 2019-05-14 | 2022-01-20 | Tyme, Inc. | Compositions and methods for treating cancer |
| CA3157855A1 (en) * | 2019-10-15 | 2021-04-22 | Tyme, Inc. | Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer |
| AU2021207666A1 (en) * | 2020-01-17 | 2022-09-01 | Tyme, Inc. | Tyrosine derivatives for modulating cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029547A (en) * | 1974-07-01 | 1977-06-14 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Biologically active substance, bestatin, and production thereof |
| LT3351246T (lt) * | 2001-02-19 | 2019-07-10 | Novartis Pharma Ag | Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui |
| JP2002326955A (ja) * | 2001-04-27 | 2002-11-15 | Nippon Kayaku Co Ltd | 無再発生存期間延長剤 |
| ES2706070T3 (es) * | 2012-01-17 | 2019-03-27 | Tyme Inc | Terapia de combinación para el tratamiento del cáncer |
-
2017
- 2017-03-15 EP EP17714095.1A patent/EP3429583A1/en not_active Withdrawn
- 2017-03-15 CA CA3016446A patent/CA3016446A1/en not_active Abandoned
- 2017-03-15 WO PCT/US2017/022386 patent/WO2017160895A1/en not_active Ceased
- 2017-03-15 MX MX2018011101A patent/MX2018011101A/es unknown
- 2017-03-15 US US16/084,578 patent/US20190091252A1/en not_active Abandoned
- 2017-03-15 JP JP2018548163A patent/JP2019508443A/ja active Pending
- 2017-03-15 KR KR1020187029154A patent/KR20180116437A/ko not_active Withdrawn
- 2017-03-15 CN CN201780016911.5A patent/CN109195601A/zh active Pending
- 2017-03-15 AU AU2017232348A patent/AU2017232348A1/en not_active Abandoned
- 2017-03-15 BR BR112018068027A patent/BR112018068027A2/pt not_active Application Discontinuation
- 2017-03-15 EA EA201892051A patent/EA201892051A1/ru unknown
-
2018
- 2018-08-21 IL IL261278A patent/IL261278A/en unknown
- 2018-09-11 PH PH12018501943A patent/PH12018501943A1/en unknown
-
2020
- 2020-07-17 US US16/931,521 patent/US20200345753A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3016446A1 (en) | 2017-09-21 |
| PH12018501943A1 (en) | 2019-06-17 |
| EP3429583A1 (en) | 2019-01-23 |
| US20200345753A1 (en) | 2020-11-05 |
| IL261278A (en) | 2018-10-31 |
| CN109195601A (zh) | 2019-01-11 |
| JP2019508443A (ja) | 2019-03-28 |
| US20190091252A1 (en) | 2019-03-28 |
| AU2017232348A1 (en) | 2018-09-06 |
| MX2018011101A (es) | 2018-11-22 |
| WO2017160895A1 (en) | 2017-09-21 |
| BR112018068027A2 (pt) | 2019-01-08 |
| KR20180116437A (ko) | 2018-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123557T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη της δραστηριοτητας της αργινασης | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| EP4438117A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX391501B (es) | Agentes inductores de apoptosis | |
| EA201890749A1 (ru) | ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| EA201691421A1 (ru) | Гетероарилы и их применение | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| EA201692437A1 (ru) | Комбинация | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| EA201591599A1 (ru) | Ингибиторы ido | |
| EA201690306A1 (ru) | Ингибиторы ido | |
| EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| EP4234552A3 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
| EA201892051A1 (ru) | Фармацевтические композиции для лечения злокачественного новообразования | |
| EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| EA201792580A1 (ru) | Ингибиторы ido |